These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 30249531

  • 1. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients.
    Ciftciler R, Demiroglu H, Buyukasık Y, Okay M, Aksu S, Sayınalp N, Malkan UY, Haznedaroglu IC, Ozcebe O, Goker H.
    Transfus Apher Sci; 2018 Dec; 57(6):752-755. PubMed ID: 30249531
    [Abstract] [Full Text] [Related]

  • 2. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
    Miyamoto T, Nagafuji K, Fujisaki T, Uchida N, Matsue K, Henzan H, Ogawa R, Takase K, Aoki T, Hidaka M, Teshima T, Taniguchi S, Akashi K, Harada M, Japan Study Group for Cell Therapy and Transplantation (JSCT).
    Int J Hematol; 2018 Apr; 107(4):468-477. PubMed ID: 29243031
    [Abstract] [Full Text] [Related]

  • 3. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M.
    Cancer; 2014 Mar 15; 120(6):855-63. PubMed ID: 24338939
    [Abstract] [Full Text] [Related]

  • 4. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, Yataganas X, Hellenic Cooperative Group.
    Cancer; 2003 Apr 01; 97(7):1721-31. PubMed ID: 12655529
    [Abstract] [Full Text] [Related]

  • 5. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, Personeni A, Bellavita P, Rodeghiero F, Barbui T.
    Haematologica; 1998 Jul 01; 83(7):627-35. PubMed ID: 9718868
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
    Tangchitpianvit K, Rattarittamrong E, Chai-Adisaksopha C, Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, Tantiworawit A, Norasetthada L.
    Hematology; 2021 Dec 01; 26(1):355-364. PubMed ID: 33853503
    [Abstract] [Full Text] [Related]

  • 7. One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
    Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, Pigneux A, BGMT Study Group.
    Br J Haematol; 2005 May 01; 129(3):403-10. PubMed ID: 15842665
    [Abstract] [Full Text] [Related]

  • 8. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
    Fedele PL, Avery S, Patil S, Spencer A, Haas M, Wei A.
    Intern Med J; 2014 Aug 01; 44(8):757-63. PubMed ID: 24863325
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
    Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Mikesch JH, Kaufmann M, Hänel M, Jost E, Brümmendorf TH, Fransecky L, Kraus S, Einsele H, Niemann D, Neubauer A, Kullmer J, Seggewiss-Bernhard R, Görner M, Held G, Kaiser U, Scholl S, Hochhaus A, Reinhardt HC, Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H, Röllig C, Study Alliance Leukemia (SAL).
    J Cancer Res Clin Oncol; 2023 Jul 01; 149(8):4611-4621. PubMed ID: 36167894
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry.
    Chanswangphuwana C, Polprasert C, Owattanapanich W, Kungwankiattichai S, Rattarittamrong E, Rattanathammethee T, Limvorapitak W, Saengboon S, Niparuck P, Puavilai T, Julamanee J, Saelue P, Wanitpongpun C, Nakhakes C, Prayongratana K, Sriswasdi C.
    Clin Lymphoma Myeloma Leuk; 2022 Oct 01; 22(10):e915-e921. PubMed ID: 35792033
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 14. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
    Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M.
    Am J Hematol; 2014 Apr 15; 89(4):395-8. PubMed ID: 24375514
    [Abstract] [Full Text] [Related]

  • 15. Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
    Zhang W, Ding Y, Wu H, Chen Y, Lu H, Chen C, Fu J, Wang W, Liang A, Zou S.
    Medicine (Baltimore); 2014 Dec 15; 93(27):e134. PubMed ID: 25501050
    [Abstract] [Full Text] [Related]

  • 16. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
    Mantovani L, Hasenclever D, Krahl R, Pönisch W, Herold M, Pasold R, Fiedler F, Dölken G, Kämpfe D, Schmoll HJ, Súbert R, Kubel M, Niederwieser D, Helbig W, East German Hematology and Oncology Group (OSHO).
    Leuk Lymphoma; 2002 Feb 15; 43(2):265-74. PubMed ID: 11999557
    [Abstract] [Full Text] [Related]

  • 17. Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
    Ochs MA, Perissinotti AJ, Marini BL, Burke PW, Bixby DL, Pettit KM, Benitez LL.
    Leuk Res; 2021 Mar 15; 102():106517. PubMed ID: 33561633
    [Abstract] [Full Text] [Related]

  • 18. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
    Wang L, Hu J, Sun Y, Huang H, Chen J, Li J, Ma J, Li J, Liang Y, Wang J, Li Y, Yu K, Hu J, Jin J, Wang C, Wu D, Xiao Y, Huang X.
    Medicine (Baltimore); 2016 Jan 15; 95(4):e2560. PubMed ID: 26825897
    [Abstract] [Full Text] [Related]

  • 19. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Kolla BC, Halim NAA, Cao Q, Sachs Z, Warlick E, Weisdorf D, Ho AYL, Chuan WG, Lao Z, He F.
    Br J Haematol; 2021 Jul 15; 194(1):140-144. PubMed ID: 33843048
    [Abstract] [Full Text] [Related]

  • 20. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M, Lee D, Coutsouvelis J, Patil S, Opat S, Walker P, Schwarer A, Salem H, Avery S, Spencer A, Wei A.
    Intern Med J; 2013 Mar 15; 43(3):294-7. PubMed ID: 22757980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.